Journals / Journal of Biotechnology and Strategic Health Research / 2017 / Mikrobiyota

Microbiota and Cancer

Mikrobiyota ve Kanser

Pages
123–131
Publication Date
2017-11-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to assess the role of microbiota in carcinogenesis and their effects on response to cancer treatments and toxicity, based on the data obtained from recent studies in this review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is a major public health problem.
📊
Key Findings & Data:Today, despite the very important developments in oncology, cancer is still not in the category of curative diseases.
💡
Conclusion & Impact:We aimed to assess the role of microbiota in carcinogenesis and their effects on response to cancer treatments and toxicity, based on the data obtained from recent studies in this review.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Kanser · Karsinogenes · Mikrobiyota

Abstract

Cancer is a major public health problem. Today, despite the very important developments in oncology, cancer is still not in the category of curative diseases. However, signifi cant steps are being taken in this direction by the identifi cation of factors that play a role in the stages of complex carcinogenesis. Recent data from the human microbiology project have shown that commensal microorganism species living on the epithelial surfaces of the body play an active role in this process and are also associated with personal responses to cancer treatment and toxicity. As a result, further exposure of a major factor with key roles in cancer development and treatment stages will reduce personal, social and economic losses associated with cancer. We aimed to assess the role of microbiota in carcinogenesis and their effects on response to cancer treatments and toxicity, based on the data obtained from recent studies in this review.

Özet

Kanser, önemli bir halk sağlığı sorunudur. Günümüzde, onkoloji alanındaki çok önemli gelişmelere rağmen halen kanser küratif hastalıklar kategorisinde değildir. Ancak, kompleks karsinogenez aşamalarında rol oynayan faktörlerin saptanması ile bu yolda önemli adımlar atılmaktadır. İnsan Mikrobiyota projesi kapsamında son dönemde elde edilen veriler, vücudumuzun epitelyal yüzeylerinde yaşayan kommensal mikroorganizma türlerinin bu süreçte aktif rol aldığını, aynı zamanda kanser tedavisine verilen kişisel yanıtlar ve toksisite ile de ilişkili olduğunu göstermiştir. Sonuç olarak, kanser oluşumu ve tedavisi aşamalarında anahtar role sahip major bir faktörün daha ortaya çıkarılması, kansere bağlı kişisel, toplumsal ve ekonomik kayıpları azaltacaktır. Biz, bu derlemede, yakın zamanda yapılan çalışmalardan elde edilen verilere dayanılarak, Mikrobiyotanın, karsinogenezdeki rolünü ve kanser tedavilerine yanıt ve toksisite üzerine etkilerini değerlendirmeyi amaçladık.

🔖

Cite This Article

GENÇ, A. C., HACIBEKİROĞLU, İ. (2017). Microbiota and Cancer. Journal of Biotechnology and Strategic Health Research, Mikrobiyota, 123–131. https://ajindex.com/articles/774623

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108
  2. Xu Z, Knight R. Dietary effects on human gut microbiome diversity. The British journal of nutrition. 2015;113 Suppl:S1-5
  3. Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in infl ammation, carcinogenesis, and cancer therapy. European journal of immunology. 2015;45(1):17-31
  4. Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: Gut microbiota: the neglected endocrine organ. Molecular endocrinology (Baltimore, Md). 2014;28(8):1221-38
  5. Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes & nutrition. 2011;6(3):209-40
  6. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. Journal of the American College of Cardiology. 2007;50(16):1561-9
  7. Fuentealba C, Figuerola F, Estévez AM, Bastías JM, Muñoz O. Bioaccessibility of lignans from fl axseed (Linum usitatissimum L.) determined by singleβbatch in vitro simulation of the digestive process. Journal of the science of food and agriculture. 2014;94(9):1729-38. 8. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology. 2012;13(6):607-15
  8. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007;449(7164):804-10
  9. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nature reviews Cancer. 2017;17(5):271-85
  10. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA: a cancer journal for clinicians. 2017;67(4):326-44
  11. Belkaid Y, Hand TW. Role of the microbiota in immunity and infl ammation. Cell. 2014;157(1):121-41
  12. De Santis S, Cavalcanti E, Mastronardi M, Jirillo E, Chieppa M. Nutritional Keys for Intestinal Barrier Modulation. Frontiers in immunology. 2015;6:612
  13. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nature reviews Immunology. 2014;14(3):141-53
  14. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite bu